Less than 1% of the cases with Angelman syndrome (AS) are caused by chromosomal rearrangements. This category of AS is not well defined and may manifest atypical phenotypes. Here, we report a girl with AS due to der(13)t(13;15)(q14.1;q12)mat. SNP array detected the precise deletion/duplication points and the parental origin of the 15q deletion. Multicolor FISH confirmed a balanced translocation t(13;15)(q14.1;q12) in her mother. Her facial appearance showed some features of dup(13)(pter→q14). Also, she lacked the most characteristic and unique behavioral symptoms of AS, i.e., frequent laughter, happy demeanor, and easy excitability. A review of the literature indicated that AS cases caused by chromosomal rearrangements can be classified into 2 major categories and 4 groups. The first category is paternal uniparental disomy 15, which is subdivided into isodisomy by de novo rob(15;15) and heterodisomy caused by paternal translocation. The second category is the deletion of the AS locus due to maternal reciprocal translocation, which is subdivided into 2 groups associated with partial monosomy by 3:1 segregation and partial trisomy by adjacent-2 segregation. Classification into these categories facilitates the understanding of the mechanisms of chromosomal rearrangements and helps in accurate diagnosis and genetic counseling of these rare forms of AS.

1.
Akahoshi K, Fukai K, Kato A, Kimiya S, Kubota T, Spritz RA: Duplication of 15q11.2-q14, including the P gene, in a woman with generalized skin hyperpigmentation. Am J Med Genet 104:299-302 (2001).
2.
Akahoshi K, Spritz RA, Fukai K, Mitsui N, Matsushima K, Ohashi H: Mosaic supernumerary inv dup(15) chromosome with four copies of the P gene in a boy with pigmentary dysplasia. Am J Med Genet A 126A:290-292 (2004).
3.
Albrecht U, Sutcliffe JS, Cattanach BM, Beechey CV, Armstrong D, et al: Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. Nat Genet 17:75-78 (1997).
4.
Angelman H: ‘Puppet' children. A report on three cases. Dev Med Child Neurol 7:681-688 (1965).
5.
Bower BD, Jeavons PM: The ‘happy puppet' syndrome. Arch Dis Child 42:298-302 (1967).
6.
Burke LW, Wiley JE, Glenn CC, Driscoll DJ, Loud KM, et al: Familial cryptic translocation resulting in Angelman syndrome: implications for imprinting or location of the Angelman gene? Am J Hum Genet 58:777-784 (1996).
7.
Butler MG, Bittel DC, Kibiryeva N, Talebizadeh Z, Thompson T: Behavioral differences among subjects with Prader-Willi syndrome and type I or type II deletion and maternal disomy. Pediatrics 113:565-573 (2004).
8.
Cafferkey M, Ahn JW, Flinter F, Ogilvie C: Phenotypic features in patients with 15q11.2(BP1-BP2) deletion: Further delineation of an emerging syndrome. Am J Med Genet A 164A:1916-1922 (2014).
9.
Christian SL, Fantes JA, Mewborn SK, Huang B, Ledbetter DH: Large genomic duplicons map to sites of instability in the Prader-Willi/Angelman syndrome chromosome region (15q11-q13). Hum Mol Genet 8:1025-1037 (1999).
10.
Cooper EM, Hudson AW, Amos J, Wagstaff J, Howley PM: Biochemical analysis of Angelman syndrome-associated mutations in the E3 ubiquitin ligase E6-associated protein. J Biol Chem 279:41208-41217 (2004).
11.
Cox DM, Butler MG: The 15q11.2 BP1-BP2 microdeletion syndrome: A review. Int J Mol Sci 16:4068-4082 (2015).
12.
Dagli AI, Mueller J, Williams CA: Angelman syndrome, in Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, et al (eds): Gene Reviews® (University of Washington, Seattle 1993-2016). http://www.ncbi.nlm.nih.gov/books/NBK1144/, last update May 14, 2015 (accessed April 27, 2016).
13.
Dindot SV, Antalffy BA, Bhattacharjee MB, Beaudet AL: The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology. Hum Mol Genet 17:111-118 (2008).
14.
Flori E, Biancalana V, Girard-Lemaire F, Favre R, Flori J, et al: Difficulties of genetic counseling and prenatal diagnosis in a consanguineous couple segregating for the same translocation (14;15)(q11;q13) and at risk for Prader-Willi and Angelman syndromes. Eur J Hum Genet 12:181-186 (2004).
15.
Fridman C, Varela MC, Nicholls RD, Koiffmann CP: Unusual clinical features in an Angelman syndrome patient with uniparental disomy due to a translocation 15q15q. Clin Genet 54:303-308 (1998).
16.
Greenberg F, Ledbetter DH: Deletions of proximal 15q without Prader-Willi syndrome. Am J Med Genet 28:813-820 (1987).
17.
Horsthemke B, Wagstaff J: Mechanisms of imprinting of the Prader-Willi/Angelman region. Am J Med Genet A 146A:2041-2052 (2008).
18.
Hultén M, Armstrong S, Challinor P, Gould C, Hardy G, et al: Genomic imprinting in an Angelman and Prader-Willi translocation family. Lancet 338:638-639 (1991).
19.
Jauch A, Robson L, Smith A: Investigations with fluorescence in situ hybridization (FISH) demonstrate loss of the telomeres on the reciprocal chromosome in three unbalanced translocations involving chromosome 15 in the Prader-Willi and Angelman syndromes. Hum Genet 96:345-349 (1995).
20.
Ji Y, Walkowicz MJ, Buiting K, Johnson DK, Tarvin RE, et al: The ancestral gene for transcribed, low-copy repeats in the Prader-Willi/Angelman region encodes a large protein implicated in protein trafficking, which is deficient in mice with neuromuscular and spermiogenic abnormalities. Hum Mol Genet 8:533-542 (1999).
21.
Jiang Y, Armstrong D, Albrecht U, Atkins CM, Noebels JL, et al: Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron 21:799-811 (1998).
22.
Jiang Y, Lev-Lehman E, Bressler J, Tsai TF, Beaudet AL: Genetics of Angelman syndrome. Am J Hum Genet 65:1-6 (1999).
23.
Kosaki R, Migita O, Takahashi T, Kosaki K: Two distinctive classic genetic syndromes, 22q11.2 deletion syndrome and Angelman syndrome, occurring within the same family. Am J Med Genet A 149A:702-705 (2009).
24.
Mignon-Ravix C, Depetris D, Luciani JJ, Cuoco C, Krajewska-Walasek M, et al: Recurrent rearrangements in the proximal 15q11-q14 region: a new breakpoint cluster specific to unbalanced translocations. Eur J Hum Genet 15:432-440 (2007).
25.
Poyatos D, Guitart M, Gabau E, Brun C, Mila M, et al: Severe phenotype in Angelman syndrome resulting from paternal isochromosome 15. J Med Genet 39:E4 (2002).
26.
Ranganath P, Agarwal M, Phadke SR: Angelman syndrome and prenatally diagnosed Prader-Willi syndrome in first cousins. Am J Med Genet A 155A:2788-2790 (2011).
27.
Schinzel A: Catalogue of Unbalanced Chromosome Aberrations in Man, ed 2, pp 570-574 (Walter de Gruyter, Berlin 2001).
28.
Schinzel A, Schmid W: Different forms of incomplete trisomy 13. Mosaicism and partial trisomy for the proxim. Humangenetik 22:287-298 (1974).
29.
Schwanitz G, Grosse KP, Semmelmayer U, Mangold H: Partial trisomy 13 in a family with balanced translocation (13 q-;16 q plus) (author's transl). Monatsschr Kinderheilkd 122:337-342 (1974).
30.
Smeets DF, Hamel BC, Nelen MR, Smeets HJ, Bollen JH, et al: Prader-Willi syndrome and Angelman syndrome in cousins from a family with a translocation between chromosomes 6 and 15. N Engl J Med 326:807-811 (1992).
31.
Smith A, den Dulk G: A severely retarded male with deletion of chromosomes 15 (pter leads to q13) and 10 (q 26 leads to qter). J Med Genet 19:77 (1982).
32.
Smith A, Deng ZM, Beran R, Woodage T, Trent RJ: Familial unbalanced translocation t(8;15)(p23.3;q11) with uniparental disomy in Angelman syndrome. Hum Genet 93:471-473 (1994).
33.
Tonk V, Schultz RA, Christian SL, Kubota T, Ledbetter DH, Wilson GN: Robertsonian (15q;15q) translocation in a child with Angelman syndrome: evidence of uniparental disomy. Am J Med Genet 66:426-428 (1996).
34.
Torisu H, Yamamoto T, Fujiwaki T, Kadota M, Oshimura M, et al: Girl with monosomy 1p36 and Angelman syndrome due to unbalanced der(1) transmission of a maternal translocation t(1;15)(p36.3;q13.1). Am J Med Genet A 131:94-98 (2004).
35.
Vanlerberghe C, Petit F, Malan V, Vincent-Delorme C, Bouquillon S, et al: 15q11.2 microdeletion (BP1-BP2) and developmental delay, behaviour issues, epilepsy and congenital heart disease: A series of 52 patients. Eur J Med Genet 58:140-147 (2015).
36.
Wenger SL, Cummins JH: Fluorescent in situ hybridization for evaluation of Prader-Willi and Angelman syndromes. Am J Med Genet 57:639 (1995).
37.
Wenger SL, Sell SL, Painter MJ, Steele MW: Inherited unbalanced subtelomeric translocation in a child with 8p- and Angelman syndromes. Am J Med Genet 70:150-154 (1997).
38.
Williams CA, Beaudet AL, Clayton-Smith J, Knoll JH, Kyllerman M, et al: Angelman syndrome 2005: updated consensus for diagnostic criteria. Am J Med Genet A 140:413-418 (2006).
39.
Williams CA, Driscoll DJ, Dagli AI: Clinical and genetic aspects of Angelman syndrome. Genet Med 12:385-395 (2010).
40.
Yamasaki K, Joh K, Ohta T, Masuzaki H, Ishimaru T, et al: Neurons but not glial cells show reciprocal imprinting of sense and antisense transcripts of Ube3a. Hum Mol Genet 12:837-847 (2003).
41.
Yesodharan D, Thampi MV, Koshy T, Nampoothiri S: Recurrence of Angelman syndrome in siblings: challenges in genetic counseling. Indian J Pediatr 81:292-295 (2014).
42.
Yip MY: Uniparental disomy in Robertsonian translocations: strategies for uniparental disomy testing. Transl Pediatr 3:98-107 (2014).
43.
Yokoyama-Rebollar E, Ruiz-Herrera A, Lieberman-Hernández E, Del Castillo-Ruiz V, Sánchez-Sandoval S, et al: Angelman syndrome due to familial translocation: unexpected additional results characterized by microarray-based comparative genomic hybridization. Mol Cytogenet 8:27 (2015).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.